Key facts
- It has raised $590K; the latest was Angel (individual) ($90K) in Jan 2026.
- Notable investors include Y Combinator.
- Rhizome AI has filed 1 Form D with the SEC, most recently Dec 2025 ($50K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Rhizome AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Rhizome AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rhizome AI
Developer of a regulatory intelligence platform intended to support regulatory research and decision-making. The company's platform searches and analyzes public regulatory materials from the food and drug administration, interprets guidance, historical decisions and review precedents, links regulatory expectations to development stages for drugs, biologics and combination products, supports regulatory strategy and submission planning and organizes complex regulatory information in a structured manner, enabling pharmaceutical and life sciences teams to assess regulatory risk, improve consistency of regulatory interpretation and support informed development and submission decisions.
- Sector
- Information Technology
- HQ
- Jersey City, NJ, United States
- Founded
- 2023
- Employees
- 4
- Website
- rhizomeai.com/
- Ownership
- Privately Held (backing)
Rhizome AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rhizome AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rhizome AI in its N-PORT filings yet. We sweep new filings monthly.